Official Title
Clinical and Biological Characteristics of Critically Ill Patients With COVID-19 Admitted to Pediatric Intensive Care Unit
Brief Summary

In this prospective longitudinal cohort the investigators reported the clinical, and biological characteristics of all critically ill patients admitted in the pediatric intensive care unit (PICU) of Bicêtre Hospital during the 2019 coronavirus disease (COVID-19) pandemics. Patients were older than 37 weeks of gestational age. No upper limit was set as the unit was transiently converted into a pediatric "adult COVID-19" intensive care unit.

Detailed Description

All patients will be monitored during their PICU stay.

Clinical characteristics include: age, gender, co-morbidities, organ support therapies
(mechanical ventilation, renal replacement therapy, extracorporeal membrane oxygenation,
vasopressors), organ complications (pulmonary embolism, acute respiratory distress syndrome,
renal failure, heart failure) and function, infective complications (ventilator associated
pneumonia, central line associated bloodstream infection, pulmonary access, sepsis, septic
shock), microbiologic and viral identification, 7-day and 28-day mortality.

Biological characteristics include:

- Admission workup: qualitative and quantitative Ig, ferritin, creatinine kinase,
complement study (C3,C4,CH50),

- Daily workup: blood cells count, arterial blood gas analysis, lactate, electrolytes,
albumin, blood urea nitrogen, creatinine, hemostasis (fibrinogen, factor V, II+VII,
factor X, prothrombin time, antiXa activity, activated cephalin time, D-dimer),
C-reactive protein, procalcitonin.

- Twice weekly workup: circulating cells phenotyping (T cell and subclass including Treg,
B cell, Natural Killer cell, myeloid derived suppressor cell, neutrophils), interleukin
6.

- Bone marrow analysis when indicated by attending staff.

Unknown status
COVID19
Pediatric ALL
Infection
Critical Illness
SARS-CoV Infection
Eligibility Criteria

Inclusion Criteria:

- Patients suspected or confirmed of severe acute respiratory syndrome Coronavirus 2
infection

- No opposition from patients or legal representatives after study information

- Patients admitted to the pediatric intensive care unit of Bicêtre Hospital, Assistance
Publique Hôpitaux de Paris - Paris Saclay University

- Between March 15, 2020 to June 31, 2021

Exclusion Criteria:

- Patient or legal representative refusal to participate

Eligibility Gender
All
Eligibility Age
Minimum: N/A ~ Maximum: N/A
Countries
France
Locations

Pediatric Intensive Care and Neonatal Medicine, Bicêtre Hospital, AP-HP PAris Saclay University
Le Kremlin-Bicêtre, France

Investigator: Clemence Marais, MD, MSc
Contact: +33145213205
clemence.marais@aphp.fr

Contacts

Pierre Tissieres, MD, DSc
+33145213205
pierre.tissieres@aphp.fr

Clemence Marais, MD, MSc
+33145213205
clemence.marais@aphp.fr

Pierre Tissieres, MD, DSc, Principal Investigator
Bicêtre Hospital

Bicetre Hospital
NCT Number
Keywords
Children
monitoring
immunodepression
HLA-DR
myeloid derived suppressor cell
neutrophil
Phenotype
MeSH Terms
Infections
Communicable Diseases
COVID-19
Severe Acute Respiratory Syndrome
Critical Illness